Hikma Pharmaceuticals Plc - Company Profile
Powered by 
All the data and insights you need on Hikma Pharmaceuticals Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Hikma Pharmaceuticals Plc Strategy Report
- Understand Hikma Pharmaceuticals Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Hikma Pharmaceuticals Plc (Hikma Pharmaceuticals) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones, and respiratory system, among others. It offers generics in various forms including tablets, capsules, solutions, and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments, and hospital purchasing organizations. The company markets its products in the UK, the Middle East, and North Africa (MENA) and Europe and Rest of the World. Hikma Pharmaceuticals is headquartered in London, England, the UK.
Headquarters
United Kingdom
Address
1 New Burlington Place, London, England, W1S2HR
Website
www.hikma.com
Telephone
44 20 73992760
No of Employees
8,967
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HIK (LON)
Revenue (2022)
$2.9B
14.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
1.1%
(2022 vs 2021)
Market Cap*
$4.9B
Net Profit Margin (2022)
XYZ
-11.5%
(2022 vs 2021)
* As of and is in US$
Hikma Pharmaceuticals Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Injectables: | Amoclan |
| Fentanyl | Blopress |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with AFT Pharmaceuticals to commercialize Combogesic IV in Saudi Arabia, Jordan, and Iraq. |
| 2024 | New Products/Services | In February, the company introduced Fentanyl Citrate Injection, USP, in 25mcg/0.5mL and 50mcg/mL doses. |
| 2024 | New Products/Services | In February, the company introduced COMBOGESIC IV injection in the US. |
Competitor Comparison
| Key Parameters | Hikma Pharmaceuticals Plc | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Pfizer Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | Switzerland | United States of America | Switzerland |
| City | London | New Brunswick | Basel | New York | Basel |
| State/Province | England | New Jersey | - | New York | - |
| No. of Employees | 8,967 | 131,900 | 103,605 | 88,000 | 76,057 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Said Darwazah | Chairman | Executive Board | - | - |
| Riad Mishlawi | Chief Executive Officer; Director | Executive Board | 2023 | - |
| Khalid Nabilsi | Chief Financial Officer | Senior Management | 2011 | - |
| Hussein Arkhagha | Chief People Officer | Senior Management | 2023 | - |
| Mazen Darwazah | President - MENA; Executive Vice Chairman | Executive Board | 2014 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward